There were 626 press releases posted in the last 24 hours and 184,373 in the last 365 days.

Herpes Zoster Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook

Approximately 6+ key companies are developing therapies for Herpes Zoster treatment. Curevo Vaccine has its drug candidates in the most advanced stage (Phase I). An increase in the prevalence of the disease and an increase in the elderly population will lead to cutting-edge technological developments for the effective treatment of the herpes zoster.

/EIN News/ -- Los Angeles, USA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Herpes Zoster Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook 

Approximately 6+ key companies are developing therapies for Herpes Zoster treatment.  Curevo Vaccine has its drug candidates in the most advanced stage (Phase I). An increase in the prevalence of the disease and an increase in the elderly population will lead to cutting-edge technological developments for the effective treatment of the herpes zoster.

DelveInsight’s “Herpes Zoster Pipeline Insight” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Herpes Zoster pipeline landscapes. It comprises Herpes Zoster pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Herpes Zoster therapeutics assessment by product type, stage, route of administration, and molecule type and highlights the inactive Herpes Zoster pipeline products.     

Some of the key takeaways from the Herpes Zoster Pipeline Report  

  • Major companies such as Curevo Vaccine, GeneOne Life Science, Shulov Innovative Science, Vaccitech, EyeGene, Nanoviricides, and others are developing potential drug candidates to improve Herpes Zoster treatment scenario. 
  • CRV-101 is being developed and investigated in a Phase I clinical trial to prevent Shingles in older adults. CRV-101 is an investigational adjuvanted subunit vaccine for the indication of prevention of Herpes Zoster in older adults.
  • A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV).
  • Vaccitech is a clinical-stage biopharmaceutical company engaged in discovering and developing novel immunotherapeutics and vaccines to treat and prevent infectious diseases and cancer. The company is currently evaluating its drug candidate VTP-400 in IND-enabling studies for the prevention of Herpes zoster.
  • Shulov Innovative Science completed a Phase I clinical study on healthy volunteers. This Phase I is suitable for several indications such as Herpes Labialis, Herpes Zoster, Atopic Dermatitis, and Burns.

Get an overview of pipeline landscape @ Herpes Zoster Clinical Trials Analysis 

Herpes Zoster, also known as Shingles, is a localized, blistering, and painful rash caused by the varicella-zoster virus’s reactivation (VZV).  The first line of treatment for Herpes Zoster and the most widely used agents for zoster infection are antiviral agents such as Acyclovir, valacyclovir, and famciclovir. 

Herpes Zoster Emerging Drugs

  • CRV-101: Curevo Vaccine

CRV-101 is an investigational adjuvanted subunit vaccine to indicate the Herpes Zoster prevention in older adults. It is a next-generation shingles vaccine candidate designed to maximize CMI protection by combining the gE protein antigen with its proprietary adjuvant. The vaccine is in Phase I clinical studies to prevent shingles in adults.

  • EG-HZ: EyeGene

A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA09, an adjuvant system. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed.

  • GLS-5100: GeneOne Life Science

GLS-5100 is a DNA-based varicella-zoster virus vaccine encoding an antigen involved in virus latency. GLS-5100 induces no safety concerns and can be used in immunosuppressed persons. The vaccine is in the preclinical stage for the treatment of Herpes Zoster.

For further information, refer to the detailed report @ Herpes Zoster Pipeline Therapeutics 

Scope of Herpes Zoster Pipeline Drug Insight    

  • Coverage: Global 
  • Major Players: 6+ Key Players
  • Prominent Players: Curevo Vaccine, GeneOne Life Science, Shulov Innovative Science, Vaccitech, EyeGene, Nanoviricides, and many others.   
  • Key Drugs Profiles: 6+ Products
  • Phases:  

·       Herpes Zoster Therapies Late-stage (Phase III)  
·       Herpes Zoster Therapies Mid-stage (Phase II)
·       Herpes Zoster Therapies Early-stage (Phase I) 
·       Herpes Zoster Preclinical stage and Discovery candidates     
·       Discontinued and Inactive candidates  

  • Mechanism of Action:

·      Immunostimulants
·    Glycoprotein inhibitors
·    Immediate early protein inhibitors

  • Molecule Types:   

·       Gene therapy 
·      Monoclonal Antibody 
·     Small molecule 
·      Peptides
·      Polymer   

  • Route of Administration:

·     Subretinal  
·      Parenteral 
·      Oral
·      Intravitreal
·      Topical 

  • Product Types:

·       Monotherapy
·       Combination
·       Mono/Combination 

Key Questions regarding Current Herpes Zoster Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

  • What are the current options for Herpes Zoster treatment?
  • How many companies are developing therapies for the treatment of Herpes Zoster? 
  • How many are Herpes Zoster emerging therapies in the early-stage, mid-stage, and late development stages to treat Herpes Zoster? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Herpes Zoster market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Herpes Zoster?  
  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Herpes Zoster therapies? 
  • What are the critical designations that have been granted for the emerging therapies for Herpes Zoster? 
  • How many patents are granted and pending for the emerging therapies to treat Herpes Zoster?   

Table of Contents

1 Herpes Zoster Report Introduction
2 Herpes Zoster Executive Summary
3 Herpes Zoster Overview
4 Herpes Zoster Pipeline Therapeutics
5 Herpes Zoster Therapeutic Assessment
6 Herpes Zoster – DelveInsight’s Analytical Perspective In-depth Commercial Assessment
7 Herpes Zoster Late Stage Products (Phase III)
8 Herpes Zoster Mid Stage Products (Phase II)
9 Herpes Zoster Early Stage Products (Phase I)
9.1 CRV-101: Curevo Vaccine
10 Herpes Zoster Preclinical and Discovery Stage Products
10.1 GLS-5100: GeneOne Life Science
11 Herpes Zoster Inactive Products
12 Herpes Zoster Key Companies
13 Herpes Zoster Key Products
14 Herpes Zoster Unmet Needs
15 Herpes Zoster Market Drivers and Barriers
16 Herpes Zoster Future Perspectives and Conclusion
17 Herpes Zoster Analyst Views
18  Appendix
19 About DelveInsight

Get a customized pipeline report @ Herpes Zoster Drugs Pipeline Report  

Other Reports

Browse Blog Posts   

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.


Contact Us:

Shruti Thakur 

info@delveinsight.com   

+1(919)321-6187 

www.delveinsight.com 

 

Primary Logo